Early post-BMT liver function in children with acute leukemia conditioned for allo-BMT with busulfan-containing and with FTBI-containing preparative regimens

Bone Marrow Transplantation

Volumn 22, Issue SUPPL. 4, 1998, Pages

  Wachowiak, J ^a   Boruczkowski, D ^a   Malicki, J ^b   Chobot Musialkiewicz U ^a  

^a Institute of Paediatrics   (Poland)

^b Greatpoland Cancer Center   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALTEPLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; HEPARIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; METHOTREXATE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; ENZYME ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER DISEASE; LIVER FUNCTION; LIVER TOXICITY; LIVER VEIN OBSTRUCTION; MALE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ADOLESCENT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIVER; LIVER FUNCTION TESTS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 0032421011     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Locasciuli A, Alberti A, de Bock R et al. Impact of liver disease and hepatic infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group - Infectious Diseases Working Party. Bone Marrow Transplant 1994; 14: 833-837.
2. Rozman C, Carreras E, Qian C et al. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75-80.
3. Ribas A, Gale RP . Should people with hepatitis C virus infection receive a bone marrow transplant ? Bone Marrow Transplant 1997; 19: 97-99.
4. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting reults of cancer treatment. Cancer 1981; 47: 207-214.
5. Glucksber H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
6. Deeg HJ, Cottler-Fox M. Clinical spectrum and pathophysiology of acute graft versus host disease. In Graft-versus-hiost disease: immunology, pathophysiology, and treatment (eds. Burakoff SJ, Deeg HJ, Ferrara J and Atkinson J), pp. 311-335, Marcel Dekker Inc. New York, 1990.
7. Attal M, Huguet F, Rubie H et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective randomized trial. Blood 1992; 79: 2834-2840.
8. 1 for prevention of lifer veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 1990; 74: 277-281.
9. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
10. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation, a cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
11. Frickhofen N, Weisneth M, Jainta C et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998-2004.
12. Shulman HM, Hinterberger W. Hepatic veno-occlusive disease - liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 197-214.
13. Carreras E, Graneňa A, Rozman C. Hepatic veno-occlusive disease after bone marrow transplant. Blood rev 1993; 7: 43-51.
14. Olive T, Badell Y, Verdeguer A et al. Incidence of veno-occlusive disease (VOD) of the liver in children. Bone Marrow Transplant 1998; 21 (suppl 1): S217.
15. Shuhart MC, McDonald GB. Gastrointestinal and hepatic complications. In: Bone marrow transplantation (eds. Forman SJ, Blume KG and Thomas ED), pp. 454-481, Blackwell Scientific Publ., Boston, 1994.
16. Méresse V, Hartmann O, Vassal G. et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135-141.
17. Okayak MF, Weinberg K, Kohn D. et al. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical out come. Bone Marrow Transplant 1991; 7: 467-474.
18. Morgan M, Dodds A, Atkinson K. et al. The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br J Haematol 1991; 77: 529-534.